Does BPC-157 really work in humans?

No human RCT studies in 2026. Solid data comes only from preclinical studies in rodents: Cerovecki 2010 (ligament healing), Chang 2011 (tenocytes), Seiwerth 2018 (angiogenesis). Human anecdotal feedback is largely positive on tendinopathies. Biological plausibility: cytoprotective paracrine mechanisms documented in preclinical seem translatable. Very favorable preclinical safety profile (no dose-dependent toxicity). In 2026, use remains 'research chemical' with informed decision accepting absence of human RCT proof. To distinguish from placebo in clinical practice: impossible without RCT.

Secretagogues vs exogenous HGH: what difference?

Fundamental difference: secretagogues (Ipamorelin, GHRP, CJC) stimulate endogenous GH release by the pituitary, preserving physiological pulsatility. Exogenous HGH delivers recombinant GH directly, creating chronic supraphysiological levels. Consequences: (1) Safety profile: secretagogues less likely to induce insulin resistance, massive retention, cardiomegaly. (2) Effect: exogenous HGH more powerful in absolute (higher IGF-1) but more marked adverse effects. (3) Cost: secretagogues $200-400/month vs HGH $300-700/month. (4) Legality: medicinal HGH has MA (adult/child GH deficiency); secretagogues remain research chemicals.

What side effects of GH-stimulating peptides?

Variable by molecule. (1) All secretagogues: moderate water retention, possible early-cycle lethargy, increased hunger (GHRP-6 particularly, GHRP-2 moderately, Ipamorelin little). (2) Cortisol: GHRP-2 and GHRP-6 moderately elevate cortisol and prolactin; Ipamorelin is selective and lacks this effect (Raun 1998). (3) Glucose: all GH-stimulating peptides elevate IGF-1 and may induce moderate insulin resistance in predisposed users (MK-677 particularly, Nass 2008). (4) Carpal tunnel syndrome: especially on exogenous HGH at high doses, rare on secretagogues. (5) Chronic elevated IGF-1: theoretical oncological risk debated (Renehan 2008).

BPC-157 + TB-500: should they be stacked?

Attractive theoretical synergy: complementary mechanisms (BPC-157 cytoprotection + healing, TB-500 tissue regeneration and angiogenesis via actin). No clinical studies of the combination. In practice, many users combine BPC-157 250 µg/d + TB-500 2 mg/wk for 4-6 wk for major tendon injuries (partial tears, chronic tendinopathies). High combined cost (~$250-500/cycle). No documented additive effect in RCT. Reasonable choice: start BPC-157 solo, add TB-500 if insufficient response at 2-3 wk.

Can peptides replace an AAS cycle?

No for raw muscle mass. Anabolic effects of GH/IGF-1 peptides (secretagogues, IGF-1 LR3, HGH) are 5-10x more modest than bodybuilding-dose AAS. Liu 2008 (systematic review GH athletic) documents +1-3 kg lean mass on 6-12 month GH cycle, vs +5-9 kg for Test E 500 mg/wk for 12 wk. However, peptides have other roles: (1) Improved recovery (sleep, anti-inflammatory). (2) Body composition (moderate fat loss). (3) Joint and tendon (BPC-157, TB-500). (4) Subjective anti-aging. Peptides are complements to AAS cycles, not replacements.

IGF-1 LR3: safe or risky?

Significant risk profile. IGF-1 has marked insulin-like action — post-injection hypoglycemic risk if insufficient carbohydrates. Doses 40-80 µg/d in bodybuilders far exceed physiological levels. Human studies absent; literature comes from preclinical studies (Tomas 1992) and oncological cases (elevated IGF-1 associated with risk of breast, prostate, colon cancer — Renehan 2008). In 2026, IGF-1 LR3 remains an 'advanced' peptide with poorly characterized risk profile. Precautions: start low (20 µg/d), glucose monitoring, limit to 4-6 wk x 2-3 cycles/year max.

How to reconstitute and store peptides?

Reconstitution: peptides delivered as lyophilizate (dry powder), to be reconstituted with bacteriostatic water (BAC water, contains 0.9% benzyl alcohol) or sterile water for injection. Standard: 2 ml BAC per 5 mg vial = 2.5 mg/ml concentration. Injection volume: 0.1 ml = 250 µg. Storage: lyophilizate at 2-8°C up to 24 months; reconstituted at 2-8°C for 14-30 days depending on peptide (BPC-157 and CJC more stable, IGF-1 LR3 more fragile). Insulin needle 30G x 8 mm SC. Hygiene: vial alcohol swab before each draw.

Peptides and anti-doping: risk?

High for most. WADA list includes: GH secretagogues (category S2 — peptide hormones, IGF-1 and growth factors), recombinant GH, IGF-1 LR3, GHRP-2/6, MK-677. BPC-157 and TB-500: ambiguous status, BPC-157 added in 2020, TB-500 monitored. Detection: exogenous GH detectable 2-3 wk post-stop by isoform method; secretagogues more difficult but indirect markers (IGF-1, P-III-NP) used. Tested-sport athletes must avoid these products. 'Accidental' contamination of peptide-containing supplements documented: risk even via products not labeled as peptides.

Best recovery peptides in 2026 — 10 molecules ranked

Methodology

Rankings based on 4 weighted criteria. (1) Data profile: number and quality of studies (human RCT > phase 2 > preclinical). Most peptides have primarily preclinical studies (rodents, in vitro), with a few phase 1-2 human studies. (2) Mechanism and biological plausibility: peptides acting via well-documented pathways (GHS-R receptor for ghrelin mimetics, cytoprotective paracrine action for BPC-157) are ranked higher. (3) Safety profile: few documented adverse effects at physiological doses, simple monitoring. (4) Market availability and quality: product availability, counterfeit rate, logistical complexity (lyophilizate reconstitution, cold chain storage). Oral peptides (MK-677) or sublingual (TB-500 spray) have superior comfort to injectable SC. Primary sources: Sigalos 2018 (safety/efficacy GHRH-GHRP), Raun 1998 (ipamorelin selective GHS), Chang 2011 (BPC-157 tendon), Cerovecki 2010 (BPC-157 ligament), Seiwerth 2018 (BPC-157 angiogenesis), Nass 2008 (MK-677 elderly RCT), Teichman 2006 (CJC-1295 GH/IGF-1 humans).

1. BPC-157 250-500 µg/d for 4-6 wk — the "cytoprotective" peptide
BPC-157 (Body Protection Compound) is a pentadecapeptide derived from human gastric juice, widely studied preclinically for its tendon, ligament and tissue healing effects. Cerovecki 2010 (rat) and Chang 2011 (rat tenocytes) document accelerated post-injury healing. Seiwerth 2018 confirms the pro-angiogenic role. Human studies absent but very favorable safety profile (Crockford 2010 on thymosin-like family).
Dose / Duration
BPC-157 250-500 µg/d SC for 4-6 wk (injection near injured area if possible, otherwise abdomen). Reconstitution: 5 mg powder + 2 ml bacteriostatic water = 2500 µg/ml. Dose: 0.1-0.2 ml/d.
Target audience
Athletes with tendon injuries (tendinopathies, partial tears), post-injury recovery period, AAS users complementing cycle (tendon synergy). Informed decision accepting absence of human data.
Pros
- + Accelerated tendon and ligament healing (Chang 2011)
- + Local and systemic anti-inflammatory effect
- + Favorable safety profile (preclinical)
- + No HPG suppression
- + Effect on connective tissues
Cons
- − No human RCT studies
- − Preclinical studies only (rodents)
- − Black market: highly variable quality
- − Unclear legal status (research chemical)
- − Reconstitution and storage required
2. TB-500 (Thymosin Beta-4) 2 mg/wk for 4-6 wk — the "regeneration" peptide
TB-500 is a synthetic fragment of endogenous Thymosin Beta-4. Goldstein 2005 and Crockford 2010 document the pro-angiogenic, pro-cell-migratory and healing effect via actin binding. Preclinical studies on cardiac injuries (Kupatt 2005), tendon and skin. No human RCT studies. Often stacked with BPC-157 for healing synergy.
Dose / Duration
TB-500 2-2.5 mg/wk SC in 1-2 doses for 4-6 wk. Possible loading dose: 5 mg/wk for 2 wk then 2.5 mg/wk maintenance. Cold-chain reconstitution.
Target audience
Athletes with cardiac injuries (post-myocarditis, in medicalized rehabilitation), chronic tendon injuries, athletes accepting non-RCT profile. Very informed decision.
Pros
- + Tissue regeneration effect (Goldstein 2005)
- + Synergy with BPC-157 (complementary mechanisms)
- + Vascular effect (angiogenesis)
- + No HPG suppression
- + Infrequent dosing (1-2 inj/wk)
Cons
- − No human clinical studies
- − High cost (~$150-300 for 4-6 wk)
- − Black market: frequent counterfeits
- − Demanding storage and reconstitution
- − Preclinical studies only
3. CJC-1295 (no DAC) + Ipamorelin (100 + 100 µg x 3x/d) — the classic GH combo
'Gold standard' combo of modern GH secretagogues. CJC-1295 without DAC is a short-acting GHRH analog; Ipamorelin is a selective GHRP/ghrelin mimetic (Raun 1998, Sigalos 2018). Synergy: CJC stimulates via GHRH receptor, Ipamorelin via GHS-R receptor, GH release amplified by summation. GH pulsatility preserved (vs supraphysiological exogenous GH). Teichman 2006 documents GH/IGF-1 elevation in humans.
Dose / Duration
CJC-1295 no DAC 100 µg + Ipamorelin 100 µg SC in 3 injections/d (wake, post-workout, bedtime) for 8-12 wk. Lyophilizate + bacteriostatic water reconstitution.
Target audience
Athletes seeking improved recovery and sleep without exogenous GH, post-AAS cycle in recovery, intermediate users accepting the logistics. Good choice for users >35 with reduced endogenous GH.
Pros
- + GH pulsatility preserved (vs exogenous GH)
- + Human studies (Teichman 2006, Sigalos 2018)
- + Effect on recovery, deep sleep, body composition
- + Favorable safety profile
- + No HPG suppression
Cons
- − Moderate-high cost (~$200-400/month)
- − Logistics of frequent injections (3x/d)
- − Reconstitution and storage required
- − Modest effects vs exogenous GH
- − Black market: variable quality
4. CJC-1295 DAC + Ipamorelin (2 mg/wk + 100 µg x 2/d) — the simplified GH combo
Logistically simpler variant: CJC-1295 with DAC (Drug Affinity Complex) has half-life ~8 days, allowing 1-2 injections/wk instead of 3/d. Ipamorelin remains at 2 doses/d. More sustained GH/IGF-1 elevation ('GH bleed'), criticized by physiologists who note loss of physiological pulsatility. Logistic vs optimal hormonal profile compromise.
Dose / Duration
CJC-1295 with DAC 2 mg/wk SC + Ipamorelin 100 µg x 2/d SC for 8-12 wk.
Target audience
Users preferring simple logistics over optimal hormonal profile, prior experience with secretagogues, baseline without strong family oncological history.
Pros
- + Simplified logistics (CJC 1-2x/wk)
- + Sustainably elevated IGF-1
- + Body composition effect
- + Improved adherence
- + Intermediate cost
Cons
- − GH pulsatility lost ("bleed")
- − Possibly faster tachyphylaxis
- − Less solid clinical studies than without DAC
- − Potential GHS-R receptor desensitization
- − Chronic elevated IGF-1 — theoretical oncological risk (Renehan 2008)
5. Ipamorelin solo 100-200 µg x 2-3/d for 8 wk — the selective GHRP
Ipamorelin is the most selective and best tolerated GHRP/ghrelin mimetic: Raun 1998 documents selective GH release without effects on prolactin, cortisol, ACTH (unlike GHRP-6 and GHRP-2). Sigalos 2018 confirms safety profile. More modest but cleaner effect than a CJC + GHRP combo. Often first-line to evaluate personal tolerance.
Dose / Duration
Ipamorelin 100-200 µg SC x 2-3 doses/d (ideally wake + bedtime, 3rd dose post-workout if practiced) for 8-12 wk.
Target audience
First secretagogue experience, users sensitive to prolactin/cortisol effects, seeking a 'clean' GH effect without excess. Good choice for users >40.
Pros
- + Selective profile (Raun 1998) — no prolactin/cortisol peak
- + Excellent tolerance
- + Solid human studies (Sigalos 2018)
- + No HPG suppression
- + First secretagogue to try
Cons
- − More modest effect than CJC + GHRP combo
- − Logistics 2-3 inj/d
- − Moderate cost (~$100-200/month)
- − Lower appetite effect than GHRP-6
- − Black market: variable quality
6. GHRP-2 100-200 µg x 3/d for 8 wk — the "max GH peak" GHRP
GHRP-2 is a more potent GHRP than Ipamorelin in absolute GH elevation, but with more marked side effects (elevated cortisol, moderate prolactin, increased appetite). Bowers 1984 documents the GH-stimulating effect of hexapeptides. Higher GH peak but less 'clean' hormonal profile. Good choice for raw performance-oriented users.
Dose / Duration
GHRP-2 100-200 µg SC x 3 doses/d for 8 wk. Often combined with CJC-1295 no DAC for synergy.
Target audience
Users in difficult mass gaining (low appetite), seeking a more marked GH effect than Ipamorelin, normal baseline cortisol profile. Not on tight cuts.
Pros
- + Higher GH peak than Ipamorelin
- + Appetite effect (useful if difficulty eating in surplus)
- + Solid preclinical studies (Bowers 1984)
- + Moderate cost
- + Deep sleep effect
Cons
- − Moderately elevated cortisol and prolactin
- − Increased hunger (weight management in cutting)
- − Logistics 3 inj/d
- − Sometimes marked water retention
- − Black market: variable quality
7. GHRP-6 100-200 µg x 2-3/d for 8 wk — the "appetite" GHRP
GHRP-6 is the ancestor of modern GHRPs (Bowers 1984), with GH-stimulating effect similar to GHRP-2 but with a very marked 'appetite' effect via direct stimulation of endogenous ghrelin. Often used in mass gaining to facilitate caloric surplus in users with low appetite. Cortisol/prolactin effects present but variable.
Dose / Duration
GHRP-6 100-200 µg SC x 2-3 doses/d for 8 wk. Appetite effect visible 15-30 min post-injection.
Target audience
Users in mass gaining with low natural appetite, powerlifting/strongman off-season, seeking a direct caloric effect. Not on cuts or if strict weight management required.
Pros
- + Very marked appetite effect (useful mass gain)
- + Significant GH peak
- + Moderate cost
- + Deep sleep effect
- + Compatible with AAS cycle
Cons
- − Moderately elevated cortisol and prolactin
- − Sometimes excessive hunger (difficult food control)
- − Water retention
- − Logistics 2-3 inj/d
- − Black market: variable quality
8. IGF-1 LR3 40-80 µg/d for 4-6 wk — the "local" growth
IGF-1 LR3 is an IGF-1 human analog with increased half-life (~20-30h vs 10-12 min native IGF-1) by chemical modification (Long R3). Direct anabolic effect on muscle via IGF-1 receptor. Tomas 1992 documents anabolic effects in rodents. Very limited human studies. Marked hypoglycemic risk (insulin-like action). High cost and very variable market quality.
Dose / Duration
IGF-1 LR3 40-80 µg/d SC, ideally post-workout (local effect stimulated by exercise) for 4-6 wk. Limit to 2-3 cycles/year. Glucose monitoring.
Target audience
Very advanced athletes on cycle, post-muscle injury, normal baseline glucose, close monitoring. Very informed decision accepting absence of RCT.
Pros
- + Direct anabolic effect on muscle
- + "Local" effect by site-specific injection
- + Synergy with intense training
- + Cellular hypertrophic effect
- + Extended half-life (1 injection/d)
Cons
- − Possible hypoglycemia (insulin-like effect)
- − High cost (~$300-600 cycle)
- − Black market: frequent counterfeits (expensive peptide)
- − Very limited human studies
- − Chronic elevated IGF-1: theoretical oncological risk (Renehan 2008)
9. MK-677 (Ibutamoren) 25 mg/d for 12-16 wk — the oral secretagogue
MK-677 is an oral non-peptide GH secretagogue: GHS-R agonist mimicking ghrelin. Nass 2008 (RCT phase 2, 65 elderly subjects, 2 years) documents +1.1 kg lean mass at 25 mg/d and sustainably elevated IGF-1. Major logistical comfort (oral pill) vs injectable peptides. Glucose effect to monitor (moderate insulin resistance). No HPG suppression.
Dose / Duration
MK-677 25 mg/d single evening dose (deep sleep effect) for 8-16 wk. Fasting glucose monitoring W0, W4, W8, W12. HbA1c at start and end.
Target audience
Users preferring oral over injection, post-AAS cycle for GH support, quality sleep prioritized. Not for pre-diabetics or those with strong family oncological history.
Pros
- + No injection — maximum comfort
- + Solid human clinical studies (Nass 2008)
- + Marked deep sleep effect
- + Sustainably elevated IGF-1
- + No HPG suppression
Cons
- − Strongly increased appetite
- − Disturbed fasting glucose (moderate insulin resistance)
- − Early-cycle lethargy
- − Sometimes marked water retention
- − Moderate-high cost
10. HGH (somatropin) 2-4 IU/d for 6-12 months — exogenous GH
Exogenous GH (recombinant human somatropin) at 'bodybuilding' physio-supraphysiological doses (2-4 IU/d) for body recomposition and anti-aging. Holt 2008 (GH/IGF-1 and sport review), Liu 2008 (systematic review GH athletic) document modest effect on lean mass and fat loss, but non-negligible adverse effects (insulin resistance, retention, carpal tunnel syndrome, possible cardiomegaly at high doses). High annual cost.
Dose / Duration
HGH (somatropin) 2-4 IU/d SC (single morning or pre-bed dose) for 6-12 months (long cycle). Cold-chain reconstitution. Glucose, IGF-1, TSH monitoring.
Target audience
Advanced bodybuilders accepting cost and risk profile, anti-aging optimizers >40, ideal medical supervision. Not for first peptide experience.
Pros
- + Documented body composition effect
- + Marked subjective anti-aging
- + Improved recovery
- + Joint and collagen effect
- + Compatible with AAS cycles (modest synergy)
Cons
- − Very high cost (~$3000-8000/year depending on dose)
- − Insulin resistance (Moller 2009)
- − Marked water retention
- − Frequent carpal tunnel syndrome
- − Chronic elevated IGF-1: theoretical oncological risk (Renehan 2008)

Final comparison

Peptide	Main effect	Human studies	Logistics	Cost/month
BPC-157	Tendon healing	No RCT	1 inj/d SC	$100-200
TB-500	Tissue regeneration	No RCT	1-2 inj/wk SC	$150-300
CJC-1295 + Ipamorelin	GH pulsatility	Solid	3 inj/d SC	$200-400
CJC DAC + Ipamorelin	Sustained elevated IGF-1	Moderate	2-3 inj/d SC	$180-350
Ipamorelin solo	Selective GH	Solid	2-3 inj/d SC	$100-200
GHRP-2	Elevated GH peak	Moderate	3 inj/d SC	$100-200
GHRP-6	Appetite + GH	Moderate	2-3 inj/d SC	$100-200
IGF-1 LR3	Direct anabolic	Very limited	1 inj/d SC	$300-600
MK-677	Oral GH/IGF-1	Solid (Nass 2008)	1 oral/d	$50-150
Exogenous HGH	Direct GH	Solid	1 inj/d SC	$300-700

FAQ

Does BPC-157 really work in humans?: No human RCT studies in 2026. Solid data comes only from preclinical studies in rodents: Cerovecki 2010 (ligament healing), Chang 2011 (tenocytes), Seiwerth 2018 (angiogenesis). Human anecdotal feedback is largely positive on tendinopathies. Biological plausibility: cytoprotective paracrine mechanisms documented in preclinical seem translatable. Very favorable preclinical safety profile (no dose-dependent toxicity). In 2026, use remains 'research chemical' with informed decision accepting absence of human RCT proof. To distinguish from placebo in clinical practice: impossible without RCT.
Secretagogues vs exogenous HGH: what difference?: Fundamental difference: secretagogues (Ipamorelin, GHRP, CJC) stimulate endogenous GH release by the pituitary, preserving physiological pulsatility. Exogenous HGH delivers recombinant GH directly, creating chronic supraphysiological levels. Consequences: (1) Safety profile: secretagogues less likely to induce insulin resistance, massive retention, cardiomegaly. (2) Effect: exogenous HGH more powerful in absolute (higher IGF-1) but more marked adverse effects. (3) Cost: secretagogues $200-400/month vs HGH $300-700/month. (4) Legality: medicinal HGH has MA (adult/child GH deficiency); secretagogues remain research chemicals.
What side effects of GH-stimulating peptides?: Variable by molecule. (1) All secretagogues: moderate water retention, possible early-cycle lethargy, increased hunger (GHRP-6 particularly, GHRP-2 moderately, Ipamorelin little). (2) Cortisol: GHRP-2 and GHRP-6 moderately elevate cortisol and prolactin; Ipamorelin is selective and lacks this effect (Raun 1998). (3) Glucose: all GH-stimulating peptides elevate IGF-1 and may induce moderate insulin resistance in predisposed users (MK-677 particularly, Nass 2008). (4) Carpal tunnel syndrome: especially on exogenous HGH at high doses, rare on secretagogues. (5) Chronic elevated IGF-1: theoretical oncological risk debated (Renehan 2008).
BPC-157 + TB-500: should they be stacked?: Attractive theoretical synergy: complementary mechanisms (BPC-157 cytoprotection + healing, TB-500 tissue regeneration and angiogenesis via actin). No clinical studies of the combination. In practice, many users combine BPC-157 250 µg/d + TB-500 2 mg/wk for 4-6 wk for major tendon injuries (partial tears, chronic tendinopathies). High combined cost (~$250-500/cycle). No documented additive effect in RCT. Reasonable choice: start BPC-157 solo, add TB-500 if insufficient response at 2-3 wk.
Can peptides replace an AAS cycle?: No for raw muscle mass. Anabolic effects of GH/IGF-1 peptides (secretagogues, IGF-1 LR3, HGH) are 5-10x more modest than bodybuilding-dose AAS. Liu 2008 (systematic review GH athletic) documents +1-3 kg lean mass on 6-12 month GH cycle, vs +5-9 kg for Test E 500 mg/wk for 12 wk. However, peptides have other roles: (1) Improved recovery (sleep, anti-inflammatory). (2) Body composition (moderate fat loss). (3) Joint and tendon (BPC-157, TB-500). (4) Subjective anti-aging. Peptides are complements to AAS cycles, not replacements.
IGF-1 LR3: safe or risky?: Significant risk profile. IGF-1 has marked insulin-like action — post-injection hypoglycemic risk if insufficient carbohydrates. Doses 40-80 µg/d in bodybuilders far exceed physiological levels. Human studies absent; literature comes from preclinical studies (Tomas 1992) and oncological cases (elevated IGF-1 associated with risk of breast, prostate, colon cancer — Renehan 2008). In 2026, IGF-1 LR3 remains an 'advanced' peptide with poorly characterized risk profile. Precautions: start low (20 µg/d), glucose monitoring, limit to 4-6 wk x 2-3 cycles/year max.
How to reconstitute and store peptides?: Reconstitution: peptides delivered as lyophilizate (dry powder), to be reconstituted with bacteriostatic water (BAC water, contains 0.9% benzyl alcohol) or sterile water for injection. Standard: 2 ml BAC per 5 mg vial = 2.5 mg/ml concentration. Injection volume: 0.1 ml = 250 µg. Storage: lyophilizate at 2-8°C up to 24 months; reconstituted at 2-8°C for 14-30 days depending on peptide (BPC-157 and CJC more stable, IGF-1 LR3 more fragile). Insulin needle 30G x 8 mm SC. Hygiene: vial alcohol swab before each draw.
Peptides and anti-doping: risk?: High for most. WADA list includes: GH secretagogues (category S2 — peptide hormones, IGF-1 and growth factors), recombinant GH, IGF-1 LR3, GHRP-2/6, MK-677. BPC-157 and TB-500: ambiguous status, BPC-157 added in 2020, TB-500 monitored. Detection: exogenous GH detectable 2-3 wk post-stop by isoform method; secretagogues more difficult but indirect markers (IGF-1, P-III-NP) used. Tested-sport athletes must avoid these products. 'Accidental' contamination of peptide-containing supplements documented: risk even via products not labeled as peptides.

Best recovery peptides in 2026 — 10 molecules ranked

Methodology

1. BPC-157 250-500 µg/d for 4-6 wk — the "cytoprotective" peptide

BPC-157 (Body Protection Compound) is a pentadecapeptide derived from human gastric juice, widely studied preclinically for its tendon, ligament and tissue healing effects. Cerovecki 2010 (rat) and Chang 2011 (rat tenocytes) document accelerated post-injury healing. Seiwerth 2018 confirms the pro-angiogenic role. Human studies absent but very favorable safety profile (Crockford 2010 on thymosin-like family).

Dose / Duration

BPC-157 250-500 µg/d SC for 4-6 wk (injection near injured area if possible, otherwise abdomen). Reconstitution: 5 mg powder + 2 ml bacteriostatic water = 2500 µg/ml. Dose: 0.1-0.2 ml/d.

Target audience

Athletes with tendon injuries (tendinopathies, partial tears), post-injury recovery period, AAS users complementing cycle (tendon synergy). Informed decision accepting absence of human data.

Pros

+ Accelerated tendon and ligament healing (Chang 2011)
+ Local and systemic anti-inflammatory effect
+ Favorable safety profile (preclinical)
+ No HPG suppression
+ Effect on connective tissues

Cons

− No human RCT studies
− Preclinical studies only (rodents)
− Black market: highly variable quality
− Unclear legal status (research chemical)
− Reconstitution and storage required

2. TB-500 (Thymosin Beta-4) 2 mg/wk for 4-6 wk — the "regeneration" peptide

TB-500 is a synthetic fragment of endogenous Thymosin Beta-4. Goldstein 2005 and Crockford 2010 document the pro-angiogenic, pro-cell-migratory and healing effect via actin binding. Preclinical studies on cardiac injuries (Kupatt 2005), tendon and skin. No human RCT studies. Often stacked with BPC-157 for healing synergy.

Dose / Duration

TB-500 2-2.5 mg/wk SC in 1-2 doses for 4-6 wk. Possible loading dose: 5 mg/wk for 2 wk then 2.5 mg/wk maintenance. Cold-chain reconstitution.

Target audience

Athletes with cardiac injuries (post-myocarditis, in medicalized rehabilitation), chronic tendon injuries, athletes accepting non-RCT profile. Very informed decision.

Pros

+ Tissue regeneration effect (Goldstein 2005)
+ Synergy with BPC-157 (complementary mechanisms)
+ Vascular effect (angiogenesis)
+ No HPG suppression
+ Infrequent dosing (1-2 inj/wk)

Cons

− No human clinical studies
− High cost (~$150-300 for 4-6 wk)
− Black market: frequent counterfeits
− Demanding storage and reconstitution
− Preclinical studies only

3. CJC-1295 (no DAC) + Ipamorelin (100 + 100 µg x 3x/d) — the classic GH combo

'Gold standard' combo of modern GH secretagogues. CJC-1295 without DAC is a short-acting GHRH analog; Ipamorelin is a selective GHRP/ghrelin mimetic (Raun 1998, Sigalos 2018). Synergy: CJC stimulates via GHRH receptor, Ipamorelin via GHS-R receptor, GH release amplified by summation. GH pulsatility preserved (vs supraphysiological exogenous GH). Teichman 2006 documents GH/IGF-1 elevation in humans.

Dose / Duration

CJC-1295 no DAC 100 µg + Ipamorelin 100 µg SC in 3 injections/d (wake, post-workout, bedtime) for 8-12 wk. Lyophilizate + bacteriostatic water reconstitution.

Target audience

Athletes seeking improved recovery and sleep without exogenous GH, post-AAS cycle in recovery, intermediate users accepting the logistics. Good choice for users >35 with reduced endogenous GH.

Pros

+ GH pulsatility preserved (vs exogenous GH)
+ Human studies (Teichman 2006, Sigalos 2018)
+ Effect on recovery, deep sleep, body composition
+ Favorable safety profile
+ No HPG suppression

Cons

− Moderate-high cost (~$200-400/month)
− Logistics of frequent injections (3x/d)
− Reconstitution and storage required
− Modest effects vs exogenous GH
− Black market: variable quality

4. CJC-1295 DAC + Ipamorelin (2 mg/wk + 100 µg x 2/d) — the simplified GH combo

Logistically simpler variant: CJC-1295 with DAC (Drug Affinity Complex) has half-life ~8 days, allowing 1-2 injections/wk instead of 3/d. Ipamorelin remains at 2 doses/d. More sustained GH/IGF-1 elevation ('GH bleed'), criticized by physiologists who note loss of physiological pulsatility. Logistic vs optimal hormonal profile compromise.

Dose / Duration

CJC-1295 with DAC 2 mg/wk SC + Ipamorelin 100 µg x 2/d SC for 8-12 wk.

Target audience

Users preferring simple logistics over optimal hormonal profile, prior experience with secretagogues, baseline without strong family oncological history.

Pros

+ Simplified logistics (CJC 1-2x/wk)
+ Sustainably elevated IGF-1
+ Body composition effect
+ Improved adherence
+ Intermediate cost

Cons

− GH pulsatility lost ("bleed")
− Possibly faster tachyphylaxis
− Less solid clinical studies than without DAC
− Potential GHS-R receptor desensitization
− Chronic elevated IGF-1 — theoretical oncological risk (Renehan 2008)

5. Ipamorelin solo 100-200 µg x 2-3/d for 8 wk — the selective GHRP

Ipamorelin is the most selective and best tolerated GHRP/ghrelin mimetic: Raun 1998 documents selective GH release without effects on prolactin, cortisol, ACTH (unlike GHRP-6 and GHRP-2). Sigalos 2018 confirms safety profile. More modest but cleaner effect than a CJC + GHRP combo. Often first-line to evaluate personal tolerance.

Dose / Duration

Ipamorelin 100-200 µg SC x 2-3 doses/d (ideally wake + bedtime, 3rd dose post-workout if practiced) for 8-12 wk.

Target audience

First secretagogue experience, users sensitive to prolactin/cortisol effects, seeking a 'clean' GH effect without excess. Good choice for users >40.

Pros

+ Selective profile (Raun 1998) — no prolactin/cortisol peak
+ Excellent tolerance
+ Solid human studies (Sigalos 2018)
+ No HPG suppression
+ First secretagogue to try

Cons

− More modest effect than CJC + GHRP combo
− Logistics 2-3 inj/d
− Moderate cost (~$100-200/month)
− Lower appetite effect than GHRP-6
− Black market: variable quality

6. GHRP-2 100-200 µg x 3/d for 8 wk — the "max GH peak" GHRP

GHRP-2 is a more potent GHRP than Ipamorelin in absolute GH elevation, but with more marked side effects (elevated cortisol, moderate prolactin, increased appetite). Bowers 1984 documents the GH-stimulating effect of hexapeptides. Higher GH peak but less 'clean' hormonal profile. Good choice for raw performance-oriented users.

Dose / Duration

GHRP-2 100-200 µg SC x 3 doses/d for 8 wk. Often combined with CJC-1295 no DAC for synergy.

Target audience

Users in difficult mass gaining (low appetite), seeking a more marked GH effect than Ipamorelin, normal baseline cortisol profile. Not on tight cuts.

Pros

+ Higher GH peak than Ipamorelin
+ Appetite effect (useful if difficulty eating in surplus)
+ Solid preclinical studies (Bowers 1984)
+ Moderate cost
+ Deep sleep effect

Cons

− Moderately elevated cortisol and prolactin
− Increased hunger (weight management in cutting)
− Logistics 3 inj/d
− Sometimes marked water retention
− Black market: variable quality

7. GHRP-6 100-200 µg x 2-3/d for 8 wk — the "appetite" GHRP

GHRP-6 is the ancestor of modern GHRPs (Bowers 1984), with GH-stimulating effect similar to GHRP-2 but with a very marked 'appetite' effect via direct stimulation of endogenous ghrelin. Often used in mass gaining to facilitate caloric surplus in users with low appetite. Cortisol/prolactin effects present but variable.

Dose / Duration

GHRP-6 100-200 µg SC x 2-3 doses/d for 8 wk. Appetite effect visible 15-30 min post-injection.

Target audience

Users in mass gaining with low natural appetite, powerlifting/strongman off-season, seeking a direct caloric effect. Not on cuts or if strict weight management required.

Pros

+ Very marked appetite effect (useful mass gain)
+ Significant GH peak
+ Moderate cost
+ Deep sleep effect
+ Compatible with AAS cycle

Cons

− Moderately elevated cortisol and prolactin
− Sometimes excessive hunger (difficult food control)
− Water retention
− Logistics 2-3 inj/d
− Black market: variable quality

8. IGF-1 LR3 40-80 µg/d for 4-6 wk — the "local" growth

IGF-1 LR3 is an IGF-1 human analog with increased half-life (~20-30h vs 10-12 min native IGF-1) by chemical modification (Long R3). Direct anabolic effect on muscle via IGF-1 receptor. Tomas 1992 documents anabolic effects in rodents. Very limited human studies. Marked hypoglycemic risk (insulin-like action). High cost and very variable market quality.

Dose / Duration

IGF-1 LR3 40-80 µg/d SC, ideally post-workout (local effect stimulated by exercise) for 4-6 wk. Limit to 2-3 cycles/year. Glucose monitoring.

Target audience

Very advanced athletes on cycle, post-muscle injury, normal baseline glucose, close monitoring. Very informed decision accepting absence of RCT.

Pros

+ Direct anabolic effect on muscle
+ "Local" effect by site-specific injection
+ Synergy with intense training
+ Cellular hypertrophic effect
+ Extended half-life (1 injection/d)

Cons

− Possible hypoglycemia (insulin-like effect)
− High cost (~$300-600 cycle)
− Black market: frequent counterfeits (expensive peptide)
− Very limited human studies
− Chronic elevated IGF-1: theoretical oncological risk (Renehan 2008)

9. MK-677 (Ibutamoren) 25 mg/d for 12-16 wk — the oral secretagogue

MK-677 is an oral non-peptide GH secretagogue: GHS-R agonist mimicking ghrelin. Nass 2008 (RCT phase 2, 65 elderly subjects, 2 years) documents +1.1 kg lean mass at 25 mg/d and sustainably elevated IGF-1. Major logistical comfort (oral pill) vs injectable peptides. Glucose effect to monitor (moderate insulin resistance). No HPG suppression.

Dose / Duration

MK-677 25 mg/d single evening dose (deep sleep effect) for 8-16 wk. Fasting glucose monitoring W0, W4, W8, W12. HbA1c at start and end.

Target audience

Users preferring oral over injection, post-AAS cycle for GH support, quality sleep prioritized. Not for pre-diabetics or those with strong family oncological history.

Pros

+ No injection — maximum comfort
+ Solid human clinical studies (Nass 2008)
+ Marked deep sleep effect
+ Sustainably elevated IGF-1
+ No HPG suppression

Cons

− Strongly increased appetite
− Disturbed fasting glucose (moderate insulin resistance)
− Early-cycle lethargy
− Sometimes marked water retention
− Moderate-high cost

10. HGH (somatropin) 2-4 IU/d for 6-12 months — exogenous GH

Exogenous GH (recombinant human somatropin) at 'bodybuilding' physio-supraphysiological doses (2-4 IU/d) for body recomposition and anti-aging. Holt 2008 (GH/IGF-1 and sport review), Liu 2008 (systematic review GH athletic) document modest effect on lean mass and fat loss, but non-negligible adverse effects (insulin resistance, retention, carpal tunnel syndrome, possible cardiomegaly at high doses). High annual cost.

Dose / Duration

HGH (somatropin) 2-4 IU/d SC (single morning or pre-bed dose) for 6-12 months (long cycle). Cold-chain reconstitution. Glucose, IGF-1, TSH monitoring.

Target audience

Advanced bodybuilders accepting cost and risk profile, anti-aging optimizers >40, ideal medical supervision. Not for first peptide experience.

Pros

+ Documented body composition effect
+ Marked subjective anti-aging
+ Improved recovery
+ Joint and collagen effect
+ Compatible with AAS cycles (modest synergy)

Cons

− Very high cost (~$3000-8000/year depending on dose)
− Insulin resistance (Moller 2009)
− Marked water retention
− Frequent carpal tunnel syndrome
− Chronic elevated IGF-1: theoretical oncological risk (Renehan 2008)

Final comparison

Peptide	Main effect	Human studies	Logistics	Cost/month
BPC-157	Tendon healing	No RCT	1 inj/d SC	$100-200
TB-500	Tissue regeneration	No RCT	1-2 inj/wk SC	$150-300
CJC-1295 + Ipamorelin	GH pulsatility	Solid	3 inj/d SC	$200-400
CJC DAC + Ipamorelin	Sustained elevated IGF-1	Moderate	2-3 inj/d SC	$180-350
Ipamorelin solo	Selective GH	Solid	2-3 inj/d SC	$100-200
GHRP-2	Elevated GH peak	Moderate	3 inj/d SC	$100-200
GHRP-6	Appetite + GH	Moderate	2-3 inj/d SC	$100-200
IGF-1 LR3	Direct anabolic	Very limited	1 inj/d SC	$300-600
MK-677	Oral GH/IGF-1	Solid (Nass 2008)	1 oral/d	$50-150
Exogenous HGH	Direct GH	Solid	1 inj/d SC	$300-700

FAQ

Does BPC-157 really work in humans?: No human RCT studies in 2026. Solid data comes only from preclinical studies in rodents: Cerovecki 2010 (ligament healing), Chang 2011 (tenocytes), Seiwerth 2018 (angiogenesis). Human anecdotal feedback is largely positive on tendinopathies. Biological plausibility: cytoprotective paracrine mechanisms documented in preclinical seem translatable. Very favorable preclinical safety profile (no dose-dependent toxicity). In 2026, use remains 'research chemical' with informed decision accepting absence of human RCT proof. To distinguish from placebo in clinical practice: impossible without RCT.
Secretagogues vs exogenous HGH: what difference?: Fundamental difference: secretagogues (Ipamorelin, GHRP, CJC) stimulate endogenous GH release by the pituitary, preserving physiological pulsatility. Exogenous HGH delivers recombinant GH directly, creating chronic supraphysiological levels. Consequences: (1) Safety profile: secretagogues less likely to induce insulin resistance, massive retention, cardiomegaly. (2) Effect: exogenous HGH more powerful in absolute (higher IGF-1) but more marked adverse effects. (3) Cost: secretagogues $200-400/month vs HGH $300-700/month. (4) Legality: medicinal HGH has MA (adult/child GH deficiency); secretagogues remain research chemicals.
What side effects of GH-stimulating peptides?: Variable by molecule. (1) All secretagogues: moderate water retention, possible early-cycle lethargy, increased hunger (GHRP-6 particularly, GHRP-2 moderately, Ipamorelin little). (2) Cortisol: GHRP-2 and GHRP-6 moderately elevate cortisol and prolactin; Ipamorelin is selective and lacks this effect (Raun 1998). (3) Glucose: all GH-stimulating peptides elevate IGF-1 and may induce moderate insulin resistance in predisposed users (MK-677 particularly, Nass 2008). (4) Carpal tunnel syndrome: especially on exogenous HGH at high doses, rare on secretagogues. (5) Chronic elevated IGF-1: theoretical oncological risk debated (Renehan 2008).
BPC-157 + TB-500: should they be stacked?: Attractive theoretical synergy: complementary mechanisms (BPC-157 cytoprotection + healing, TB-500 tissue regeneration and angiogenesis via actin). No clinical studies of the combination. In practice, many users combine BPC-157 250 µg/d + TB-500 2 mg/wk for 4-6 wk for major tendon injuries (partial tears, chronic tendinopathies). High combined cost (~$250-500/cycle). No documented additive effect in RCT. Reasonable choice: start BPC-157 solo, add TB-500 if insufficient response at 2-3 wk.
Can peptides replace an AAS cycle?: No for raw muscle mass. Anabolic effects of GH/IGF-1 peptides (secretagogues, IGF-1 LR3, HGH) are 5-10x more modest than bodybuilding-dose AAS. Liu 2008 (systematic review GH athletic) documents +1-3 kg lean mass on 6-12 month GH cycle, vs +5-9 kg for Test E 500 mg/wk for 12 wk. However, peptides have other roles: (1) Improved recovery (sleep, anti-inflammatory). (2) Body composition (moderate fat loss). (3) Joint and tendon (BPC-157, TB-500). (4) Subjective anti-aging. Peptides are complements to AAS cycles, not replacements.
IGF-1 LR3: safe or risky?: Significant risk profile. IGF-1 has marked insulin-like action — post-injection hypoglycemic risk if insufficient carbohydrates. Doses 40-80 µg/d in bodybuilders far exceed physiological levels. Human studies absent; literature comes from preclinical studies (Tomas 1992) and oncological cases (elevated IGF-1 associated with risk of breast, prostate, colon cancer — Renehan 2008). In 2026, IGF-1 LR3 remains an 'advanced' peptide with poorly characterized risk profile. Precautions: start low (20 µg/d), glucose monitoring, limit to 4-6 wk x 2-3 cycles/year max.
How to reconstitute and store peptides?: Reconstitution: peptides delivered as lyophilizate (dry powder), to be reconstituted with bacteriostatic water (BAC water, contains 0.9% benzyl alcohol) or sterile water for injection. Standard: 2 ml BAC per 5 mg vial = 2.5 mg/ml concentration. Injection volume: 0.1 ml = 250 µg. Storage: lyophilizate at 2-8°C up to 24 months; reconstituted at 2-8°C for 14-30 days depending on peptide (BPC-157 and CJC more stable, IGF-1 LR3 more fragile). Insulin needle 30G x 8 mm SC. Hygiene: vial alcohol swab before each draw.
Peptides and anti-doping: risk?: High for most. WADA list includes: GH secretagogues (category S2 — peptide hormones, IGF-1 and growth factors), recombinant GH, IGF-1 LR3, GHRP-2/6, MK-677. BPC-157 and TB-500: ambiguous status, BPC-157 added in 2020, TB-500 monitored. Detection: exogenous GH detectable 2-3 wk post-stop by isoform method; secretagogues more difficult but indirect markers (IGF-1, P-III-NP) used. Tested-sport athletes must avoid these products. 'Accidental' contamination of peptide-containing supplements documented: risk even via products not labeled as peptides.